INOVOTION (spin-off from Grenoble-Alpes University) is a biotech company with a unique in vivo technology providing efficacy and toxicity evaluations of oncology and immuno-oncology drugs, as well as biomaterial and biocompatibility tests. The assays are both in vivo, and 3Rs-compliant.
​ This unique platform provides early analysis for drug candidates from small molecules to biologics, before the classical preclinical stage. By eliminating low-value molecules and biomaterial early, INOVOTION accelerates the drug discovery process, increases R&D productivity, and reduces its costs.
​ INOVOTION built this xenograft model using immunocompetent chicken embryos for its powerful intrinsic benefits: fast, robust, affordable, and predictive. These in vivo assays will save time and give clear competitive advantages to researchers.
​
​ This next generation in vivo model covers: - Efficacy assays for anti-cancer treatments including antibodies and cellular therapies
​ - Early Toxicity assays for drug candidates
​ - Cancer models development from patient biopsies, CTCs and PDO
​ - Target Validation in oncology
​ - Multi-Cancer Screening to (re)position a treatment
​ - Biomaterial and Biocompatibility tests
​ This conference will cover several aspects of tumour growth, metastatic invasion, angiogenesis, immune cell infiltration, toxicity, and biomaterial.
​
​ After the conference, Jean Viallet will be available to discuss your research projects. Feel free to also contact him directly at contact@inovotion.com​

​​L'accès au site CEA nécéssite un laisser passer. ​​Contact ​: ​​Odile Filhol-Cochet​​​​